Mantle Cell Lymphoma | Oncology Today with Dr Neil Love: Role of BTK Inhibitors in Patients with Mantle Cell Lymphoma
Featuring perspectives from Dr Michael Wang, including the following topics: Algorithm for observation versus initiation of therapy for newly diagnosed mantle cell lymphoma (MCL) (0:00) First- and second-line therapy approaches for MCL (7:26) Case: A 45-year-old woman with relapsed MCL receiving acalabrutinib who develops severe headaches (10:21) Current role of ibrutinib in the treatment of MCL; use of single-agent venetoclax and of zanubrutinib in the treatment algorithm (14:59) Case: A 68-year-old man presenting with an enlarged spleen, no lymphadenopathy and a white blood cell count of 300,000 is diagnosed with MCL (17:48) Case: A 71-year-old man with multiregimen-relapsed, nodular type MCL presents with lymphadenopathy and a 3-cm tumor near the mediastinum (22:38) Patient selection for chimeric antigen receptor T-cell therapy (25:59) Novel and investigational therapeutic approaches for MCL (30:11) Treatment approaches for other histological variants of MCL (39:00) CME information and select publications